TP53 and cancer: To examine to what extent germline genetics primes aberrations in oncogenic signaling pathways we first conducted genome-wide association studies (GWAS) using >8500 human samples across 33 cancer types characterized by TCGA and exploiting phenotypic traits built considering 10 oncogenic signaling pathways previously described and characterized in20; considered pathway include Cell Cycle, HIPPO, MYC, NOTCH, NRF2, PI3K, RTK RAS, TGF Beta, TP53 and WNT.